It showed a dramatic effect in ALK-positive solid tumors and ALCLs.9,10 A second-generation ALK inhibitor, alectinib, was subsequently approved and showed a higher response rate than crizotinib with minimal toxicity in patients with ALK-rearranged metastatic NSCLC.11 Currently, ceritinib, brigatinib, and lorlatinib are approved in the clinical setting for ALK-rearranged NSCLC.12-14. The gene discussed is ALK; the disease is non-small cell lung carcinoma.